

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷: A61K 9/16, 9/22, 9/58	A1	(11) International Publication Number: WO 00/12067 (43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/US99/19575 (22) International Filing Date: 26 August 1999 (26.08.99) (30) Priority Data: 60/098,154 27 August 1998 (27.08.98) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Provinceline Road, P.O. Box 4000, Princeton, NJ 08543-4000 (US). (72) Inventor: RAYBURN, James, W.; 1601 N. Red Bank Road, Evansville, IN 47720 (US). (74) Agent: RYAN, Richard, P.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NOVEL PHARMACEUTICAL SALT FORM (57) Abstract The saccharinate salt of synthetic non-alkaloidal medicinal organic bases provides a novel salt form possessing improved organoleptic properties as well as reduced solubility.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL PHARMACEUTICAL SALT FORM

Cross Reference to Related Application

This application claims priority from provisional application
USSN 60/098,154 filed August 27, 1998.

5 Background of the Invention

The present invention relates to a novel salt form of certain
pharmacologically active organic bases and their preparation. The class will
be exemplified by the saccharinate salt of buspirone, a useful anti-anxiety
agent.

10 It is known that while many organic bases function as useful
pharmacologic agents, nonetheless salt forms are often pharmaceutically
preferred for reasons of enhanced solubility, ease of compounding, and
stability. It is also well accepted that oral dosing of drugs is a preferred route
of administration. However, most organic bases possess a very bitter taste
15 which, for acceptable oral administration, requires masking by various
methods familiar to pharmaceutical formulation practitioners such as the
incorporation of sweeteners, flavorings, organoleptic enhancers, and the like.

The intense bitter taste of most bases can be relieved somewhat by
substituting a salt form of the pharmacologically active agent for the base in
20 pharmaceutical formulations; e.g., the hydrochloride salt. Some salt forms of
drugs are more effective than others in reducing the objectionable taste of
the pharmaceutical formulation. It is known that patient compliance in
adhering to a drug regimen is negatively affected by pharmaceutical products
that are objectionable in taste, particularly in instances where the patient
25 disorder is accompanied by loss of appetite, nausea, and vomiting.

In U.S. 4,362,730, Räder, et al. disclosed and claimed the
saccharinate salt of vincamine, a pharmaceutically active alkaloid.
Vincamine saccharinate was described as having improved solubility and
taste characteristics. Greater solubility for the saccharinate salt of vincamine
30 differs from the reduced solubility seen for the saccharinates of the present
convention.

The present invention concerns a novel salt form of non-alkaloidal medicinal organic bases that renders the normally bitter-tasting drug much more palatable, thereby facilitating its pharmaceutical formulation for oral routes of administration where taste comes into play; such as liquid suspensions, lozenges, chewable tablets, chewing gums, and the like. When applied to synthetic organic base medicinals, as opposed to alkaloids, solubility of the salt is generally less than for more standard pharmaceutical salts such as halides, sulfates, and the like.

Detailed Description of the Invention

10 The saccharinate salt of certain non-alkaloidal organic bases provides novel salt forms demonstrating improved organoleptic properties. For certain medicinals the saccharinate salt also provides a means of sustaining drug release by virtue of decreased aqueous solubility of the saccharinate compared to more standard pharmaceutical salts such as halides, sulfates, 15 phosphates, and the like. The saccharinate salts are conveniently synthesized by salt interchange on admixture of solutions of sodium saccharinate and acid addition salts; e.g., the hydrochloride salt, of medicinal organic bases. Other salt-forming reactions, well-known to one skilled in the pharmaceutical sciences, may also be employed.

20 Various classes of orally-active non-alkaloidal synthetic medicinal organic bases are intended applications of the present invention. Some of these medicinal bases fall into the following medical use categories:

- antiinfectives such as erythromycin;
- oncolytics;
- 25 • analgesics such as codeine, meperidine, pentazocine, butorphanol, buprenorphine;
- psychopharmacologics;
- neurologics;
- anesthetics;

- respiratory agents;
- cardiovasculars/cardio-renal agents
- endocrine agents;
- metabolic agents;
- 5 • gastrointestinal agents;
- antiallergenics; and
- immunologics.

Psychopharmacologics can be subclassed as:

- 10 • anxiolytics; e.g., benzodiazepines such as alprazolam, azapirones
such as buspirone;
- antipsychotics; e.g., phenothiazines such as chlorpromazine and
thioridazine, piperazines such as fluphenazine, thioxanthenes such
as thiothixene, butyrophenones such as haloperidol,
15 dibenzoxapines such as loxapine, dihydroindolones such as
molindone; and
- affective disorder agents such as imipramine, trazodone,
nefazodone, fluoxetine, sertraline, and the like,
dextroamphetamine and methylphenidate.

20 Neurologics can be represented by procyclidine, biperiden,
amantadine and selegiline; ergotamines and methylsergide; scopolamine,
cyclizine, hydroxyzine and the like.

Anesthetics are represented by benzocaine, dibucaine, lidocaine,
procaine and the like.

Respiratory agents are represented by epinephrine, phenylephrine, phenylpropanolamine and pseudoephedrine; isoproterenol and terbutaline.

Cardiovasculars can be subclassed as:

- inotropics such as dobutamine;
- 5 • antiarrhythmics such as acecainide, disopipramide;
- β -blockers such as propranolol, atenolol, nadolol;
- calcium blockers such as diltiazem, nifedipine and nimodipine;
- vasodilators such as papaverine and isoxsuprine;
- antihypertensives such as hydralazine; and
- 10 • diuretics such as triamterene and amiloride.

Endocrine agents such as bromocryptine and clomiphene; and metabolic agents such as phenformin.

Gastrointestinal agents such as metaclopramide or cimetidine.

15 The present invention involves stable crystalline saccharinate salts of orally administrable medicinal bases. Saccharin, chemically 1,2-benzisothiazol-3(2H)-one 1,1,dioxide, is used as a sweetener, most commonly in the form of its sodium salt dihydrate. While it is used as a sweetener in pharmaceutical applications, its use is as a component of a mixture of ingredients. While saccharine provides a sweet taste in dilute
20 aqueous solutions where it is about 500 times sweeter than sugar with the sweet taste still detectable in 1:100,000 dilution; nonetheless saccharin has a bitter, metallic aftertaste. Because saccharin's taste is most pleasant in dilute solution, care must be exercised in formulating saccharin in its solid state because of a very objectionable taste.

25 By contrast the current invention relates to actual salt forms, as opposed to mixtures, comprising the organic base cation and the

saccharinate anion. In this form the medicinal has pleasant organoleptic properties even in its solid form. As such, the saccharinate salts offer the potential for pharmaceutical formulations without requiring large amounts of other organoleptic enhancers such as sweeteners, flavors, and the like which are usually required to render medicinal bases palatable. The advantages of saccharinate salts would especially be evident in formulating oral suspensions, chewable tablets, lozenges, and quick-melt dosage forms.

Another aspect of the present invention relates to the general reduction in solubility of the saccharinate salts of the non-alkaloidal medicinal bases compared to more common acid addition salts of the medicinal bases such as hydrohalide, sulfate, phosphate salts and the like. With reduced solubility drug release is slowed and extended release of the drug usually occurs. Therefore, the saccharinate salts offer a method for providing extended release dosing for certain medicinals.

The present invention is illustrated by the following examples but is not limited to them.

Example 1 - Buspirone Saccharinate

Buspirone hydrochloride (8-4[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride 4.22 g, 10 mmole) dissolved in a minimal amount of water was added to a concentrated solution of sodium saccharinate (2.05 g, 10 mmole) with stirring. The mixture was chilled and the supernatant aqueous layer decanted from the heavier oil layer which was dissolved in methylene chloride. The methylene chloride solution was washed with water and then dried (MgSO_4). The dried solution was filtered and concentrated in vacuo to a clear oil. Trituration in ether provided a pale yellow saccharinate salt, m.p. 142-145 °C.

Analysis:

Calculated for $\text{C}_{21}\text{H}_{31}\text{N}_5\text{O}_2 \cdot \text{C}_7\text{H}_5\text{NO}_3\text{S}$: C, 59.14; H, 6.38; N, 14.78; S, 5.64.

Found: C, 59.14; H, 6.46; N, 14.89; S, 5.51.

Example 2 - Taste Preference Testing

Under single-blind conditions, three small glass plates were set out for taste-testing. Plate #1 contained buspirone hydrochloride. Plate #2 contained buspirone saccharinate, and Plate #3 contained 1:1 molar equivalent amounts of buspirone hydrochloride and sodium saccharinate in the form of a physical mixture. Tasting volunteers were asked to taste each of the samples and give their preference. All volunteers selected Plate #2 (buspirone saccharinate) as the best tasting sample. By contrast, both Plates #1 and #3 were labeled as objectionable to highly objectionable in taste by the volunteers.

Claims

1. The saccharinate salt of non-alkaloidal organic medicinal bases capable of acid addition salt formation.
2. The salt of claim 1 wherein the base is a useful non-alkaloidal orally-active drug selected from the group consisting of psychopharmacologics, analgesics, neurologics, anesthetics, respiratory agents, cardiovascular-renal agents, hematologic agents, endocrine and metabolic agents, gastrointestinal agents, dermatologic agents, antiinflammatories, antiallergics, immunologics, oncolytics, and antiinfectives.
3. The salt of claim 2 wherein the base is a useful orally-active antiinfective agent.
4. The salt of claim 2 wherein the base is a useful orally-active analgesic agent.
5. The salt of claim 2 wherein the base is a useful orally-active cardiovascular-renal agent.
6. The salt of claim 2 wherein the base is a useful orally-active gastrointestinal agent.
7. The salt of claim 2 wherein the base is a useful orally-active neurologic agent.
8. The salt of claim 2 wherein the base is a useful orally-active psychopharmacologic agent.
9. The psychopharmacologic agent of claim 8 that is useful in depression.
10. The psychopharmacologic agent of claim 8 that is useful in anxiety.
11. The psychopharmacologic agent of claim 10 that is an azapirone.

12. The azapirone of claim 11 selected from buspirone and gepirone.
13. The azapirone of claim 11 is buspirone saccharinate.
14. The method of producing a saccharinate salt comprising the mixing of
a solution of an acid addition salt of the medicinal base with a solution of
5 sodium saccharinate.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/19575

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 9/16, 9/22, 9/58

US CL : 424/441, 497; 514/951

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/441, 497; 514/951

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 1,288,002 A (SYNERHOLM et. al.) 12 February 1962, Table at the bottom of page 2	1, 2, 5, 14
---		---
Y		3, 4, 6-13
Y, P	US 5,837,277 A (HAYWARD) 17 November 1998, col. 3, line 64.	1-14

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 NOVEMBER 1999

Date of mailing of the international search report

19 JAN 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

TAMTHOM N. TRUONG

Telephone No. (703) 308-1235